[go: up one dir, main page]

ATE362380T1 - Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie - Google Patents

Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie

Info

Publication number
ATE362380T1
ATE362380T1 AT03008324T AT03008324T ATE362380T1 AT E362380 T1 ATE362380 T1 AT E362380T1 AT 03008324 T AT03008324 T AT 03008324T AT 03008324 T AT03008324 T AT 03008324T AT E362380 T1 ATE362380 T1 AT E362380T1
Authority
AT
Austria
Prior art keywords
hapten
carrier conjugates
disclosed
drug abuse
conjugates
Prior art date
Application number
AT03008324T
Other languages
English (en)
Inventor
Philip A Swain
Victoria C Schad
Julia L Greenstein
Mark A Exley
Barbara S Fox
Stephen P Powers
Malcolm L Gefter
Thomas J Briner
Original Assignee
Xenova Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/563,673 external-priority patent/US5760184A/en
Application filed by Xenova Res Ltd filed Critical Xenova Res Ltd
Application granted granted Critical
Publication of ATE362380T1 publication Critical patent/ATE362380T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03008324T 1995-03-31 1996-03-27 Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie ATE362380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41497195A 1995-03-31 1995-03-31
US08/563,673 US5760184A (en) 1995-03-31 1995-11-28 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same

Publications (1)

Publication Number Publication Date
ATE362380T1 true ATE362380T1 (de) 2007-06-15

Family

ID=27022809

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03008324T ATE362380T1 (de) 1995-03-31 1996-03-27 Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
AT96910595T ATE254930T1 (de) 1995-03-31 1996-03-27 Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96910595T ATE254930T1 (de) 1995-03-31 1996-03-27 Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie

Country Status (10)

Country Link
US (1) US6054127A (de)
EP (1) EP0814843B1 (de)
AT (2) ATE362380T1 (de)
AU (1) AU5374996A (de)
CA (1) CA2216658C (de)
DE (2) DE69637089T2 (de)
DK (2) DK0814843T3 (de)
ES (2) ES2287379T3 (de)
PT (1) PT814843E (de)
WO (1) WO1996030049A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5817770A (en) 1997-03-21 1998-10-06 Drug Abuse Sciences, Inc. Cocaethylene immunogens and antibodies
SE9801923D0 (sv) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
EP1263438B1 (de) 2000-03-15 2006-05-17 Wolfgang Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
WO2002046234A1 (en) * 2000-12-07 2002-06-13 The Scripps Research Institute Cocaine haptens
KR20120041739A (ko) * 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
US20060024768A1 (en) * 2004-07-29 2006-02-02 Saladax Biomedical, Inc. Taxol immunoassay
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
CA2702680A1 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
FR2952935B1 (fr) * 2009-11-20 2011-12-02 Sanofi Aventis Procede de preparation du n-biotinyl-6-aminocaproate de n succinimidyle
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
CN108409749B (zh) * 2018-01-30 2019-09-06 中国农业科学院蜜蜂研究所 钩吻素己半抗原和全抗原及其制备方法与应用
WO2021242823A1 (en) * 2020-05-27 2021-12-02 Behnam Babak Compositions and Methods for Treating Cocaine, Nicotine, and Methamphetamine Dependence

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) * 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3888886A (en) * 1972-06-08 1975-06-10 Mobil Oil Corp Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst
US4045420A (en) * 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US4197237A (en) * 1973-06-01 1980-04-08 Syva Company Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof
US4207307A (en) * 1977-01-21 1980-06-10 Research Corporation Simultaneous immunoassay of multiple antigens and assay for cocaine metabolites
SU792869A1 (ru) * 1979-03-30 1982-03-30 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов барбитурова кислота-иммуногенный носитель
US4376825A (en) * 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
SU1123704A1 (ru) * 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4791067A (en) * 1987-06-25 1988-12-13 Fisher Scientific Co. Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent
DE3884731D1 (de) * 1987-10-09 1993-11-11 Ube Industries Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin.
JP2921574B2 (ja) * 1988-02-01 1999-07-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンの担体分子としてのｔ細胞のエピトープ
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5026827A (en) * 1988-09-02 1991-06-25 Matsushita Electric Industrial Co., Ltd. Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0363041A1 (de) * 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoklonaler Antikörper gegen Morphin, Bereitung von monoklonalen Antikörpern, Testsatz und Verfahren zur Bestimmung von Morphin
DK0386644T3 (da) * 1989-03-10 1997-10-13 Hoffmann La Roche Reagenser til bestemmelse af lægemidler
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
US5096838A (en) * 1989-11-27 1992-03-17 Abbott Laboratories Barbiturate assay compositions and methods
CH678394A5 (de) * 1990-08-22 1991-09-13 Cerny Erich H
JPH04182499A (ja) * 1990-11-14 1992-06-30 Matsushita Electric Ind Co Ltd エクゴニン・タンパク質コンジュゲート及びその誘導体
US5233042A (en) * 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
US5302715A (en) * 1992-04-06 1994-04-12 Biosite Diagnostics, Inc. Benzodiazepine derivatives
AU4377793A (en) * 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
DE69332637T2 (de) * 1993-03-04 2003-10-23 Matsushita Electric Industrial Co., Ltd. Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
US5871934A (en) * 1993-09-17 1999-02-16 Smithkline Beecham Corporation Screening methods using cytokine suppressive anti-inflammatory drug (CSAID) binding proteins
AU2241995A (en) * 1994-04-08 1995-10-30 Immulogic Pharmaceutical Corporation Pharmaceutical formulations for treating japanese cedar pollen allergy

Also Published As

Publication number Publication date
EP0814843A2 (de) 1998-01-07
DE69637089D1 (de) 2007-06-28
CA2216658A1 (en) 1996-10-03
WO1996030049A3 (en) 1997-03-06
WO1996030049A2 (en) 1996-10-03
DK0814843T3 (da) 2004-03-29
PT814843E (pt) 2004-04-30
DE69637089T2 (de) 2008-01-17
US6054127A (en) 2000-04-25
EP0814843B1 (de) 2003-11-26
AU5374996A (en) 1996-10-16
DE69630877D1 (de) 2004-01-08
ATE254930T1 (de) 2003-12-15
ES2287379T3 (es) 2007-12-16
ES2210356T3 (es) 2004-07-01
DE69630877T2 (de) 2004-11-11
DK1329226T3 (da) 2007-09-24
CA2216658C (en) 2008-05-13

Similar Documents

Publication Publication Date Title
WO1998014216A3 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
ATE362380T1 (de) Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
EP1329226A3 (de) Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie
MXPA01005511A (es) Conjugados de hapteno-portador para tratar y prevenir la adiccion a la nicotina.
EP2392345A3 (de) Haptenträgerkonjugate mit virusähnlichen Partikeln und Verwendungen davon
DE69840909D1 (de) Analoge von kokain
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
NZ314058A (en) Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer
DE59107814D1 (de) Impfstoff gegen drogen
WO2003061595A3 (en) Antibodies against and compositions containing new amphetamine derivatives
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
WO1997033620A3 (de) Verbindungen zur behandlung von tumoren
AU4073797A (en) Method of enhancing the delivery of growth factors
MD1469G2 (ro) Metodă de tratament al şocului combustional
Lafferty The therapeutic community as an interventive milieu.
RU2000105967A (ru) Способ лечения абстинентного синдрома у больных зависимостью от трамала
UA10754A (uk) Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу
UA18878A (uk) Спосіб лікуваhhя алкогольhої та hаркотичhої залежhості

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1329226

Country of ref document: EP